November 17th, 2026Don't Miss a Beat: How Prediction Markets Could Threaten Clinical Trial IntegrityAnkeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.Read more
November 10th, 2026Don't Miss a Beat: What Lp(a)HORIZON and ZEUS Teach About Clinical Trial ScienceLp(a)HORIZON and ZEUS hit their biomarker targets but not MACE. Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, unpack both at AHA 2026.Read more
November 9th, 2026Asundexian Receives FDA Approval for Secondary Stroke PreventionThe FDA approved asundexian with antiplatelet therapy after noncardioembolic ischemic stroke or high-risk TIA, based on OCEANIC-STROKE data.Read more
November 16th, 2026Diabetes Dialogue: OPTIMAL-DIABETES, Survodutide, and Orforglipron at AHA 2026Diana Isaacs, PharmD, and Natalie Bellini, DNP, review OPTIMAL-DIABETES, SYNCHRONIZE-CVOT, and ATTAIN-OSA data from AHA 2026.Read more
November 16th, 2026FDA Updates Aficamten Label With MAPLE-HCM Data in Obstructive HCMAficamten's label now includes MAPLE-HCM data, in which aficamten monotherapy improved peak VO2 by 2.3 mL/kg/min more than metoprolol at 24 weeks.Read more
November 14th, 2026Early Dupilumab in Pediatric EoE Tied to Lower Incident AsthmaChildren with eosinophilic esophagitis treated with dupilumab before age 6 had about half the asthma incidence of matched untreated peers 3.5 years later.Read more
November 14th, 2026Omalizumab Linked to 0 Epinephrine Use in Alpha-Gal SyndromeNo patients with alpha-gal syndrome needed epinephrine for a food reaction during omalizumab therapy in a 64-patient cohort presented at ACAAI 2026.Read more
November 13th, 2026Omalizumab, Remibrutinib Show Similar Early CSU Gains in Indirect AnalysisA post hoc, unmatched comparison presented at ACAAI 2026 found similar 14-day improvements in urticaria activity with omalizumab vs remibrutinib.Read more